{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964020",
  "id": "02964020",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250701",
  "time": "0731",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l990zgn71gvv.pdf",
  "summary": "### Summary of ASX Announcement: Quarterly Update (Appendix 4C Equivalent)  \n\n#### **Key Highlights**  \n- **Combogesic IV (Maxigesic IV) launch in Canada** begins this month, targeting opioid alternatives in pain management.  \n- **US licensing agreement with Hikma Pharmaceuticals extended**: Restructured profit-sharing for Combogesic IV/Rapid; Hikma to oversee all US channels (excluding Alexso\u2019s niche markets).  \n- **R&D progress**:  \n  - Pre-IND filed for antibiotic eyedrop (targeting resistant infections); IND filing planned pre-year-end.  \n  - Pre-IND upcoming for Strawberry Birthmarks topical; IND for novel iron injection by year-end.  \n  - New formulation project added (targeting ~US$180M niche market).  \n- **Pediatric expansion**: Maxigesic IV study for pediatric use planned to broaden market.  \n- **Commercial pipeline**: Five out-licensing deals completed; more in negotiation.  \n\n#### **Strategic Impact**  \n- Expands North American footprint (Canada launch, US partnership restructuring).  \n- Advances high-potential R&D assets with near-term regulatory milestones.  \n\n**No material financial data (e.g., cash balance) disclosed.**  \n\n*(Note: Omitted operational, market context, and non-material details.)*",
  "usage": {
    "prompt_tokens": 2426,
    "completion_tokens": 274,
    "total_tokens": 2700,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-30T21:54:46.334533"
}